Report cover image

Inflammatory Bowel Disease Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2025-2034

Publisher Global Market Insights
Published Aug 11, 2025
Length 174 Pages
SKU # GMI20337013

Description

The Global Inflammatory Bowel Disease Treatment Market was valued at USD 26.6 billion in 2024 and is estimated to grow at a CAGR of 5.9% to reach USD 47.2 billion by 2034.

The market growth is driven by the increasing prevalence of Crohn’s disease and ulcerative colitis, rising awareness about gastrointestinal disorders, and ongoing advancements in biologics and targeted therapies. Inflammatory bowel disease (IBD) is becoming a significant public health concern worldwide, with lifestyle changes, genetic predisposition, and environmental factors contributing to its rising incidence. As healthcare systems focus on early diagnosis and effective management, pharmaceutical companies are investing heavily in novel drug classes that improve patient outcomes, reduce hospitalizations, and enhance quality of life. The expansion of precision medicine and ongoing clinical research into next-generation biologics, biosimilars, and small-molecule therapies are further shaping the future of IBD treatment.

The Crohn’s disease segment generated USD 16.1 billion in 2024, driven by the rising prevalence of the condition across both developed and developing regions. Increasing awareness, improved diagnostic capabilities, and the growing demand for targeted biologic therapies are fueling market expansion. Patients with Crohn’s disease often require long-term management, which boosts the adoption of advanced treatment options aimed at reducing flare-ups, promoting mucosal healing, and improving quality of life. Moreover, ongoing R&D in monoclonal antibodies and novel oral therapies is further strengthening growth prospects in this segment.

The second-line treatment segment generated USD 19.7 billion in 2024 driven by patients who develop resistance or intolerance to first-line therapies increasingly turn to biologics and advanced small-molecule drugs. This segment is particularly important in managing moderate to severe cases, where conventional treatments fail to provide adequate control. The availability of diverse therapeutic classes, such as anti-TNF agents, JAK inhibitors, and integrin receptor antagonists, offers physicians more options for personalized treatment approaches. Growing clinical evidence supporting the efficacy of second-line therapies, combined with rising healthcare investments and broader reimbursement coverage, continues to drive adoption in this segment.

North America Inflammatory Bowel Disease Treatment Market generated USD 17.5 billion in 2024, owing to the high prevalence of IBD, strong healthcare infrastructure, and wide availability of advanced therapies. The region benefits from extensive R&D activities, favorable reimbursement frameworks, and the early adoption of novel biologics and small-molecule drugs. Europe follows closely, supported by rising healthcare spending, awareness programs, and biosimilar penetration. Meanwhile, the Asia Pacific region is expected to see the fastest growth, driven by urbanization, lifestyle changes, and improving diagnostic capabilities in countries like China, India, and Japan. Increasing investments in healthcare infrastructure and the expansion of pharmaceutical companies into emerging markets further enhance the region’s growth prospects.

The competitive landscape of the Global Inflammatory Bowel Disease Treatment Market is shaped by innovation, strategic alliances, and expansion of drug pipelines. Key players in the market include AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Company Limited, Pfizer Inc., Bristol-Myers Squibb Company, Amgen Inc., and Eli Lilly and Company. These companies are heavily investing in clinical trials, expanding indications for existing drugs, and developing advanced biologics and biosimilars to strengthen their positions in the global market.

Table of Contents

174 Pages
Chapter 1 Methodology
1.1 Industry coverage
1.2 Market scope and definitions
1.3 Research design
1.4 Market size estimates and calculations
1.4.1 Approach 1: Company revenue share analysis
1.4.2 Approach 2: Patient-Level Cost Modelling
1.4.3 Approach 3: Investor Presentation
1.4.4 Approach 4: Parent market analysis
1.5 Key trends for market estimates
1.6 Forecast model
1.7 Primary research & validation
1.7.1 Primary sources
1.7.2 Data mining sources
1.7.2.1 Paid sources
1.7.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360 degree synopsis
2.2 Business trends
2.2.1 Regional trends
2.2.2 Treatment type trends
2.2.3 Drug class trends
2.2.4 Route of administration trends
2.2.5 Distribution channel trends
2.3 CXO Perspectives: Strategic Imperatives
2.3.1 Key decision points for industry executives
2.3.2 Critical success factors for market players
Chapter 3 Industry Insights
3.1 Industry ecosystem
3.1.1 TAM/SAM
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of IBD
3.2.1.2 Technological advancements
3.2.1.3 Favorable reimbursement policies
3.2.1.4 Growing awareness and early diagnosis of IBD symptoms
3.2.2 Industry pitfalls and challenges
3.2.2.1 Stringent regulatory scenario
3.2.2.2 High cost of treatment
3.2.3 Market opportunities
3.2.3.1 Rising adoption of biologics and targeted therapies
3.2.3.2 Expansion in emerging markets
3.3 Growth potential analysis
3.3.1 By treatment type
3.3.2 By drug class
3.3.3 By route of administration
3.3.4 By distribution channel
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.5.3 Asia Pacific
3.6 Pipeline analysis
3.7 Investment scenarios outlook
3.8 Future market trends/ Key marketed therapies
3.9 Epidemiology scenario
3.10 Treatment switching patterns or sequencing trends
3.11 Brand analysis, 2024
3.12 Porter's analysis
3.13 PESTEL analysis
Chapter 4 Competitive Landscape
4.1 Introduction
4.1.1 AbbVie
4.1.2 Johnson & Johnson
4.1.3 Takeda Pharmaceutical Company
4.2 Company market share analysis
4.2.1 Global company market share analysis
4.2.2 North America company market share analysis
4.2.3 Europe company market share analysis
4.2.4 Asia Pacific company market share analysis
4.2.5 Latin America company market share analysis
4.2.6 MEA company market share analysis
4.3 Competitive analysis of major market players
4.4 Company matrix analysis
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Mergers and acquisitions
4.6.2 Partnerships and collaborations
4.6.3 New product launches
4.6.4 Expansion plans
Chapter 5 Inflammatory Bowel Disease Treatment Market, By Treatment Type
5.1 Crohn's disease
5.2 Ulcerative colitis
Chapter 6 Inflammatory Bowel Disease Treatment Market, By Drug Class
6.1 First-line treatment
6.1.1 Aminosalicylates
6.1.2 Corticosteroids
6.2 Second-line treatment
6.2.1 IL inhibitors
6.2.2 Anti-integrin
6.2.3 TNF inhibitors
6.2.4 JAK inhibitors
6.2.5 S1P receptor modulator
6.3 Combination therapy
6.3.1 TNF inhibitors + thiopurines
6.3.2 Other combination therapies
Chapter 7 Inflammatory Bowel Disease Treatment Market, By Route of Administration
7.1 Injectable
7.2 Oral 99
7.3 Rectal
Chapter 8 Inflammatory Bowel Disease Treatment Market, By Distribution Channel
8.1 Hospital Pharmacy
8.2 Retail Pharmacy
8.3 Online Pharmacy
Chapter 9 Inflammatory Bowel Disease Treatment Market, By Region
9.1 North America
9.2 Europe
9.3 Asia Pacific
9.4 Latin America
9.5 Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie
10.1.1 Financial Data
10.1.2 Product Landscape
10.1.3 Strategy Outlook
10.1.4 SWOT Analysis
10.2 Alvotech
10.2.1 Financial Data
10.2.2 Product Landscape
10.2.3 Strategy Outlook
10.2.4 SWOT Analysis
10.3 Amgen
10.3.1 Financial Data
10.3.2 Product Landscape
10.3.3 Strategy Outlook
10.3.4 SWOT Analysis
10.4 Biogen
10.4.1 Financial Data
10.4.2 Product Landscape
10.4.3 SWOT Analysis
10.5 Boehringer Ingelheim
10.5.1 Financial Data
10.5.2 Product Landscape
10.5.3 Strategy Outlook
10.5.4 SWOT Analysis
10.6 Celltrion
10.6.1 Financial Data
10.6.2 Product Landscape
10.6.3 Strategy Outlook
10.6.4 SWOT Analysis
10.7 Dr Falk Pharma
10.7.1 Financial Data
10.7.2 Product Landscape
10.7.3 SWOT Analysis
10.8 Eli Lily
10.8.1 Financial Data
10.8.2 Product Landscape
10.8.3 Strategic Outlook
10.8.4 SWOT Analysis
10.9 Ferring
10.9.1 Financial Data
10.9.2 Product Landscape
10.9.3 Strategy Outlook
10.9.4 SWOT Analysis
10.10 Johnson & Johnson
10.10.1 Financial Data
10.10.2 Product Landscape
10.10.3 Strategy Outlook
10.10.4 SWOT Analysis
10.11 ORGANON
10.11.1 Financial Data
10.11.2 Product Landscape
10.11.3 Strategy Outlook
10.11.4 SWOT Analysis
10.12 Pfizer
10.12.1 Financial Data
10.12.2 Product Landscape
10.12.3 Strategic Outlook
10.12.4 SWOT Analysis
10.13 Takeda Pharmaceuticals
10.13.1 Financial Data
10.13.2 Product Landscape
10.13.3 Strategic Outlook
10.13.4 SWOT Analysis
10.14 UCB
10.14.1 Financial Data
10.14.2 Product Landscape
10.14.3 Strategy Outlook
10.14.4 SWOT Analysis

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us